Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5755544 | 0.91 | OPRM1 (0.43) | OPRM1OPRD1OPRK1OPRL1KDM4C | |
| SCHEMBL1508195 | 0.82 | PGR (0.44) | GAASMN1; SMN2HTR2A | |
| SCHEMBL14101425 | 0.82 | PGR (0.44) | GAASMN1; SMN2HTR2A | |
| SCHEMBL10603757 | 0.80 | OPRM1 (0.43) | OPRM1OPRD1OPRK1OPRL1KDM4C | |
| SCHEMBL18192162 | 0.79 | HTR2A (0.43) | OPRM1GAASMN1; SMN2HTR2A | |
| SCHEMBL30337114 | 0.78 | OPRM1 (0.45) | OPRM1OPRD1OPRK1OPRL1KDM4C | |
| SCHEMBL16543135 | 0.78 | OPRM1 (0.45) | OPRM1OPRD1OPRK1OPRL1KDM4C | |
| SCHEMBL10192534 | 0.78 | OPRM1 (0.45) | OPRM1OPRD1OPRK1OPRL1KDM4C | |
| Hydrochloric Acid SCHEMBL3583361 | 0.77 | OPRM1 (0.44) | OPRM1OPRD1OPRK1OPRL1KDM4C | |
| Hydrochloric Acid SCHEMBL16536511 | 0.77 | OPRM1 (0.44) | OPRM1OPRD1OPRK1OPRL1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417384-A1 | CRYSTALS OF TETRAHYDRONAPHTHYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-12-19 | — | — | US | disclosed |
| US-12134607-B2 | Crystals of tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-05 | — | — | US | disclosed |
| EP-3617195-B1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVES AS INHIBITORS OF TROPOMYOSIN RECEPTOR KINASE A FOR THE TREATMENT OF PAIN | MOCHIDA PHARM CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-110831926-B | Tetrahydronaphtyl urea derivatives | 持田制药株式会社 | 2023-11-21 | — | — | CN | disclosed |
| US-20220348552-A1 | CRYSTALS OF TETRAHYDRONAPHTHYL UREA DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-11-03 | — | — | US | disclosed |
| US-11325895-B2 | Crystals of tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-05-10 | — | — | US | disclosed |
| US-11325895-B2 | Crystals of tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-05-10 | — | — | US | disclosed |
| US-10927079-B2 | Intermediate compound of novel tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-23 | — | — | US | disclosed |
| US-10927079-B2 | Intermediate compound of novel tetrahydronaphthyl urea derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-23 | — | — | US | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-1199307-B1 | Pharmaceutically active benzoquinazoline compounds | WELLCOME FOUND (GB) | 2004-02-25 | — | — | EP | disclosed |
| EP-0535034-B1 | PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS | WELLCOME FOUND (GB) | 2002-08-14 | — | — | EP | disclosed |
| EP-1199307-A1 | Pharmaceutically active benzoquinazoline compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 2002-04-24 | — | — | EP | disclosed |
| US-6306865-B1 | SYNTHASE INHIBITORS AND ANTITUMOR AGENTS | GLAXO WELLCOME INC. | 2001-10-23 | — | — | US | disclosed |
| US-6090941-A | Pharmaceutically active benzoquinazoline compounds | GLAXO WELLCOME INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-5663337-A | ENZYME, ANTITUMOR | GLAXO WELLCOME INC. (US) | 1997-09-02 | — | — | US | disclosed |
| US-5661155-A | THYMIDYLATE SYNTHASE INHIBITOR; ADMINISTERING TO THE MAMMAL SUFFERING FROM LEUKEMIA OR TUMOR 2-(5-(((1,2-DIHYDRO-3-METHYL-1-OXOBENZO(F)QUINAZOLINE-9-YL) METHYL)AMINO)-1-OXO-2-ISOINDOLINYL)GLUTARIC ACID OR SALTS | GLAXO WELLCOME INC. (US) | 1997-08-26 | — | — | US | disclosed |
| US-5405851-A | Administering benzoquinazoline thymidylate synthase inhibitors | BURROUGHS WELLCOME CO. (US) | 1995-04-11 | — | — | US | disclosed |
| EP-0535034-A1 | PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-04-07 | — | — | EP | disclosed |
| WO-1991019700-A1 | PHARMACEUTICALLY ACTIVE BENZOQUINAZOLINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417384-A1 | CRYSTALS OF TETRAHYDRONAPHTHYL UREA DERIVATIVE | ULK2, UTS2R, UMPS | OPRM1 31/4885OPRD1 170/4885OPRK1 60/4885 |
| US-20220348552-A1 | CRYSTALS OF TETRAHYDRONAPHTHYL UREA DERIVATIVE | ULK2, UTS2R, UMPS | OPRM1 31/4885OPRD1 170/4885OPRK1 60/4885 |
| US-10927079-B2 | Intermediate compound of novel tetrahydronaphthyl urea derivative | CCNT2, DIMT1, QTRT2 | OPRM1 1482/4885OPRD1 824/4885OPRK1 2151/4885 |
| US-11325895-B2 | Crystals of tetrahydronaphthyl urea derivative | ULK2, UTS2R, UMPS | OPRM1 31/4885OPRD1 170/4885OPRK1 60/4885 |
| US-12134607-B2 | Crystals of tetrahydronaphthyl urea derivative | ULK2, UTS2R, UMPS | OPRM1 31/4885OPRD1 170/4885OPRK1 60/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | OPRM1 184/4885OPRD1 176/4885OPRK1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.